Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction.

brexpiprazole glioblastoma glioma stem cell osimertinib survivin xenograft

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 Jul 2019
Historique:
received: 29 05 2019
revised: 26 06 2019
accepted: 03 07 2019
entrez: 10 7 2019
pubmed: 10 7 2019
medline: 10 7 2019
Statut: epublish

Résumé

Glioblastoma is a primary brain tumor associated with a poor prognosis due to its high chemoresistance capacity. Cancer stem cells (CSCs) are one of the mechanisms of chemoresistance. Although therapy targeting CSCs is promising, strategies targeting CSCs remain unsuccessful. Abnormal activation of epidermal growth factor receptors (EGFRs) due to amplification, mutation, or both of the

Identifiants

pubmed: 31284441
pii: cancers11070947
doi: 10.3390/cancers11070947
pmc: PMC6679129
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Endocr Relat Cancer. 2001 Jun;8(2):83-96
pubmed: 11397666
Oncogene. 2003 May 8;22(18):2812-22
pubmed: 12743604
J Clin Oncol. 2004 Jan 1;22(1):133-42
pubmed: 14638850
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurology. 2005 Apr 26;64(8):1444-5
pubmed: 15851741
N Engl J Med. 2005 Nov 10;353(19):2012-24
pubmed: 16282176
Cancer Res. 2006 Aug 15;66(16):7864-9
pubmed: 16912159
Cancer Res. 2006 Oct 15;66(20):10100-11
pubmed: 17047074
Cancer Res. 2007 Sep 1;67(17):7960-5
pubmed: 17804702
Science. 2007 Oct 12;318(5848):287-90
pubmed: 17872411
J Neurooncol. 2008 Oct;90(1):89-97
pubmed: 18581057
J Clin Oncol. 2009 Mar 10;27(8):1268-74
pubmed: 19204207
J Neurooncol. 2010 Jan;96(2):219-30
pubmed: 19562254
Sci Signal. 2009 Sep 08;2(87):re6
pubmed: 19738203
Cancer Cell. 2010 Apr 13;17(4):362-75
pubmed: 20385361
Neoplasia. 2010 Sep;12(9):675-84
pubmed: 20824044
Stem Cells. 2010 Nov;28(11):1930-9
pubmed: 20857497
Expert Rev Neurother. 2010 Oct;10(10):1537-44
pubmed: 20925470
Cancer Res. 2010 Dec 15;70(24):10402-10
pubmed: 21159653
Clin Cancer Res. 2011 Aug 1;17(15):4942-7
pubmed: 21622723
Stem Cells. 2011 Dec;29(12):1942-51
pubmed: 21957016
Mol Cancer. 2011 Oct 11;10:128
pubmed: 21988793
Mol Cancer Ther. 2012 Jan;11(1):204-13
pubmed: 22075159
Sci Rep. 2012;2:516
pubmed: 22816039
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11
pubmed: 23182702
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4339-44
pubmed: 23440206
J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):143-54
pubmed: 23489694
Cancer Discov. 2013 May;3(5):534-47
pubmed: 23533263
Ann Oncol. 2013 Oct;24(10):2601-6
pubmed: 23857959
Annu Rev Pathol. 2014;9:1-25
pubmed: 23937436
Nat Rev Cancer. 2013 Oct;13(10):727-38
pubmed: 24060864
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
J Neurooncol. 2014 Jan;116(2):413-9
pubmed: 24352766
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Oncotarget. 2014 Feb 28;5(4):882-93
pubmed: 24658464
JAMA Neurol. 2014 Nov;71(11):1437-44
pubmed: 25244650
Oncotarget. 2015 Jan 1;6(1):458-70
pubmed: 25473894
Cancer Med. 2015 May;4(5):643-50
pubmed: 25533314
Breast Cancer Res Treat. 2015 Jan;149(1):171-9
pubmed: 25547219
Front Oncol. 2015 Jan 29;5:5
pubmed: 25688333
Am J Psychiatry. 2015 Sep 1;172(9):870-80
pubmed: 25882325
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
Int J Clin Pract. 2015 Nov;69(11):1211-20
pubmed: 26477545
CNS Spectr. 2016 Feb;21(1):1-6
pubmed: 26899451
Int Clin Psychopharmacol. 2016 Jul;31(4):192-201
pubmed: 26963842
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
Anticancer Res. 2016 Oct;36(10):5153-5161
pubmed: 27798875
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Ther Adv Psychopharmacol. 2017 Jan;7(1):29-41
pubmed: 28101322
Ther Clin Risk Manag. 2017 Mar 10;13:299-306
pubmed: 28331332
Oncotarget. 2017 May 16;8(20):33316-33328
pubmed: 28410196
CNS Drugs. 2017 Sep;31(9):723-735
pubmed: 28791656
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
Oncotarget. 2017 Aug 3;8(42):72494-72512
pubmed: 29069805
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Ann Oncol. 2018 Mar 1;29(3):687-693
pubmed: 29293889
Perspect Psychiatr Care. 2018 Oct;54(4):507-513
pubmed: 29427512
Nature. 1985 Jan 10-18;313(5998):144-7
pubmed: 2981413
Anticancer Res. 2018 Aug;38(8):4535-4542
pubmed: 30061219
Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3786-3798
pubmed: 30315932
Anticancer Res. 2019 Feb;39(2):609-617
pubmed: 30711936
Oncotarget. 2019 May 28;10(37):3547-3558
pubmed: 31191825
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903
pubmed: 3477813

Auteurs

Shuhei Suzuki (S)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Masahiro Yamamoto (M)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan. masahiro@med.id.yamagata-u.ac.jp.

Tomomi Sanomachi (T)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Keita Togashi (K)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Department of Ophthalmology and Visual Sciences, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Asuka Sugai (A)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Shizuka Seino (S)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Takashi Yoshioka (T)

Department of Clinical Oncology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Chifumi Kitanaka (C)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Masashi Okada (M)

Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.

Classifications MeSH